Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR-2 salanersen study after onasemnogene abeparvovec in presymptomatic infants with SMA
2025-523857-32-00Phase 3Authorised
- Sponsor
- Biogen
- Start
- Aug 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of salanersen in spinal muscular atrophy (SMA) (2 arms), sponsored by Biogen. Primary endpoint: Number of participants with adverse events and serious adverse events. Planned start Aug 2026; status: authorised.
02
Drugs
salanersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2025-523857-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523857-32-00.